Mounjaro and pancreatitis: what the percentage risk actually means

What the SURMOUNT trial data and regulatory classifications actually show

Across the SURMOUNT clinical programme, which randomised thousands of adults with obesity, acute pancreatitis occurred but was not among the common adverse events reported. The tirzepatide Summary of Product Characteristics, published on the Electronic Medicines Compendium (eMC), places it in the “uncommon” tier of the standard MedDRA frequency scale, meaning the observed rate sat between roughly 0.1% and 1% of participants. That puts it above the threshold for “rare,” which is worth being clear about, but well below the “common” bracket that covers the familiar nausea, constipation and indigestion that many people notice in the first few weeks of treatment.

What matters for individual risk is that a percentage drawn from a trial population is a starting point, not a personal forecast. Your prescriber considers your full picture: whether you have had pancreatitis before, your alcohol intake, any gallbladder history, and your current triglyceride levels, all of which influence susceptibility. The trial figures describe a general population; your consultation is where those figures get translated into a decision about you.

The NHS medicines page for tirzepatide lists pancreatitis among the side effects that require you to stop treatment and seek urgent help, which is the practical message that sits behind the percentage.

What the MHRA's January 2026 safety update changed

Before January 2026, the pancreatitis risk was documented in the SmPC and prescriber guidance but had not been the subject of a standalone regulatory communication in the UK. The MHRA's Drug Safety Update changed that. It asked prescribers across all GLP-1 medicines to counsel patients on the symptoms before starting treatment and to document any relevant history.

The update did not change the approved indications or the frequency classification. It did make explicit something that good clinical practice already required: patients should know what to look for and should not delay getting help if those symptoms appear. For anyone already on tirzepatide, the update is a reminder rather than a new alarm. For anyone considering starting, it underlines why a thorough clinical assessment matters more than the speed of placing an order.

You can learn more about how this risk is weighed against the broader side-effect profile of Mounjaro, or read a detailed breakdown of the specific link between Mounjaro and pancreatitis if you want more clinical background before your consultation.

Symptoms that need same-day medical attention

Acute pancreatitis typically presents as severe pain in the upper abdomen or centre of the stomach that builds over hours, often reaching through to the back. It tends to worsen after eating and may come with nausea and vomiting that does not settle. That pattern, particularly the radiating quality and the persistence, is what distinguishes it from the ordinary stomach discomfort that many people experience when starting or increasing their Mounjaro dose.

A practical checking habit: if stomach pain is mild, comes and goes, and eases within twenty minutes, it is likely the normal GI adjustment. If it builds steadily over an hour or more and does not shift when you change position, that is the point to call 111 or go to A&E rather than waiting to see whether it passes overnight. If you are unsure whether your symptoms are connected to your medication, our page on Mounjaro causing pancreatitis sets out the clinical picture in more detail.

Alongside the pain itself, watch for fever, a rigid or very tender abdomen, or signs of dehydration from repeated vomiting. If you experience any of these, stop your injection and seek medical help the same day. The NHS guidance is unambiguous: do not restart treatment until a doctor has reviewed you.

If you believe a symptom is connected to your treatment, you or your clinician can report it directly to the MHRA through the Yellow Card scheme. That reporting is genuinely useful: post-marketing data from Yellow Card reports has contributed to every significant safety update for GLP-1 medicines in recent years, including the January 2026 communication. Suspected counterfeit pens can be flagged there too.

How a clinical assessment addresses this risk before treatment starts

The reason pancreatitis appears in the pre-treatment discussion rather than only the side-effect leaflet is that several modifiable and non-modifiable factors interact with the baseline risk. A personal or family history of pancreatitis, significant alcohol use, gallstones, and very high triglycerides all shift the risk profile, and our guide on whether Mounjaro can cause pancreatitis explains how each of these factors is understood clinically. None of these is an automatic exclusion, but each one is something a prescriber needs to know about.

At nume, a GPhC-registered Independent Prescriber reads your consultation answers the same day. A real clinician reviews your responses, not a rules engine, and if your history includes anything that touches pancreatitis risk, they can ask follow-up questions or request additional information before approving treatment. That process exists precisely because a percentage from a trial paper cannot do what a clinical conversation can.

Our prescribers also discuss what to do if symptoms develop, which is a routine part of aftercare support available seven days a week. You can find background on the clinical team at our prescriber profile page, or read through the risk factors for pancreatitis on Mounjaro if you want to come to your consultation better prepared, alongside our practical advice on how to avoid pancreatitis on Mounjaro while you are in treatment. If you are ready to discuss suitability, start your free consultation and our prescribers will cover this alongside everything else relevant to your situation.